Xenon Pharmaceuticals’ anti-seizure candidate has smashed a pivotal trial out of the park, lowering seizure rates by more than 50% for some patients as it looks to position itself to become the ...

While physicians and scientists have long known Alzheimer's disease involves the buildup of toxic protein fragments in the brain, they have struggled to understand how these harmful fragments are ...

Please provide your email address to receive an email when new articles are posted on . Seizure freedom was observed by 12 months and continued past 48 months of the open-label extension. Long-term ...